{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Number of Responders"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Number of Non Responders"}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"The response rate is the number of patients with urothelial cancer treated with erlotinib prior to cystectomy. The response is defined as the absence of residual cancer in the surgical removed tissue (i.e., pT0). A responder is defined as a participant with the pathological stage of pT0 meaning that there is no evidence of disease.","groups":[{"description":"Erlotinib 150 mg by mouth daily for 3 weeks followed by cystectomy within 24 hours of the last dose.","id":"OG000","title":"Pre-surgical Erlotinib Treatment"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"two participants did not take any eroltinib and three participants stopped erlotinib early due to intolerable side effects.","reportingStatus":"POSTED","timeFrame":"Determined at the time of surgery or cystectomy","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}